Home/ Stocks/ TIL

Instil Bio, Inc. Common Stock

TIL XNAS

$7.41 +0.01 (+0.07%) ▲ 15-min delayed

Open

$7.34

High

$7.49

Low

$7.27

Volume

11.8K

Market Cap

$49.37M

About Instil Bio, Inc. Common Stock

Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.

Sector: BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Employees: 17 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-4,204,000	$-0.62
FY 2025	$0	$-71,372,000	$-10.70
Q3 2025	$0	$-13,587,000	$-2.01
Q1 2025	$0	$-28,200,000	$-4.32

Related Market News

No specific coverage for TIL yet. Check out our latest market news or earnings calendar.

Get TIL Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Instil Bio, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.